Atlas Trials

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Clinical trial NCT03026166 · TERMINATED

Trial details

NCT number
NCT03026166
Sponsor
AbbVie
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2017-03-30
Primary completion
2019-07-03
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.